ID
16705
Descripción
Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of Study: Deviation Log
Link
https://clinicaltrials.gov/ct2/show/NCT00373425
Palabras clave
Versiones (1)
- 1/8/16 1/8/16 -
Subido en
1 de agosto de 2016
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Deviation Log, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425
Deviation Log, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
Descripción
Signature
Alias
- UMLS CUI-1
- C1519316
Descripción
Monitor Name
Tipo de datos
text
Alias
- UMLS CUI [1,1]
- C0027365
- UMLS CUI [1,2]
- C1521743
Descripción
Monitor Signature
Tipo de datos
text
Alias
- UMLS CUI [1,1]
- C1519316
- UMLS CUI [1,2]
- C1521743
Descripción
Signature Date
Tipo de datos
date
Alias
- UMLS CUI [1,1]
- C1519316
- UMLS CUI [1,2]
- C0011008
Similar models
Deviation Log, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
C1704732 (UMLS CUI [1,2])
C2985654 (UMLS CUI [1,2])
C0332307 (UMLS CUI [1,2])
C1521743 (UMLS CUI [1,2])
C1521743 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])